Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance.
Putluri N, Maity S, Kommagani R, Creighton CJ, Putluri V, Chen F, Nanda S, Bhowmik SK, Terunuma A, Dorsey T, Nardone A, Fu X, Shaw C, Sarkar TR, Schiff R, Lydon JP, O'Malley BW, Ambs S, Das GM, Michailidis G, Sreekumar A. Putluri N, et al. Among authors: das gm. Neoplasia. 2014 May;16(5):390-402. doi: 10.1016/j.neo.2014.05.007. Neoplasia. 2014. PMID: 25016594 Free PMC article.
Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation.
Konduri SD, Medisetty R, Liu W, Kaipparettu BA, Srivastava P, Brauch H, Fritz P, Swetzig WM, Gardner AE, Khan SA, Das GM. Konduri SD, et al. Among authors: das gm. Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15081-6. doi: 10.1073/pnas.1009575107. Epub 2010 Aug 9. Proc Natl Acad Sci U S A. 2010. PMID: 20696891 Free PMC article.
TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.
Mukhopadhyay UK, Oturkar CC, Adams C, Wickramasekera N, Bansal S, Medisetty R, Miller A, Swetzig WM, Silwal-Pandit L, Børresen-Dale AL, Creighton CJ, Park JH, Konduri SD, Mukhopadhyay A, Caradori A, Omilian A, Bshara W, Kaipparettu BA, Das GM. Mukhopadhyay UK, et al. Among authors: das gm. J Natl Cancer Inst. 2019 Nov 1;111(11):1202-1215. doi: 10.1093/jnci/djz051. J Natl Cancer Inst. 2019. PMID: 30990221 Free PMC article.
ESR1 and p53 interactome alteration defines mechanisms of tamoxifen response in luminal breast cancer.
Oturkar CC, Rosario SR, Hutson AD, Groman A, Edge SB, Morrison CD, Swetzig WM, Wang J, Park JH, Kaipparettu BA, Singh PK, Kumar S, Cappuccino HH, Ranjan M, Adjei A, Ghasemi M, Goey AKL, Kulkarni S, Das GM. Oturkar CC, et al. Among authors: das gm. iScience. 2024 May 15;27(6):109995. doi: 10.1016/j.isci.2024.109995. eCollection 2024 Jun 21. iScience. 2024. PMID: 38868185 Free PMC article.
35 results